Beta-1 adrenergic receptor antagonists
Beta-1 adrenergic receptor antagonists has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest paper, Apr 20, 2026: “Repurposing drugs for the prevention of vascular dementia using evidence from drug target Mendelian randomization”.
1 paper studies it4 findingsUpdated
See all 1 papers on beta-1 adrenergic receptor antagonists
- Humans1
What did studies of beta-1 adrenergic receptor antagonists find?
2Studies of beta-1 adrenergic receptor antagonists measured 2 outcomes: mean diffusivity and white matter hyperintensity volume.
Mean diffusivity
downin silico1
1 study
Mean diffusivity
downin silico1
Beta-1 adrenergic receptor antagonists decrease mean diffusivity in silico (Mendelian randomization) (causal effect = -0.18, 95% CI = -0.37-0.00).
“mean diffusivity: estimated causal effect = -0.18, 95% CI = -0.37-0.00”
In silicoMendelian randomization
Nature aging
White matter hyperintensity volume
downin silico1
1 study
White matter hyperintensity volume
downin silico1
Beta-1 adrenergic receptor antagonists decrease white matter hyperintensity volume in silico (Mendelian randomization) (causal effect = -0.03, 95% CI = -0.07-0.00).
“white matter hyperintensity volume: estimated causal effect = -0.03, 95% CI = -0.07-0.00”
In silicoMendelian randomization
Nature aging
What is beta-1 adrenergic receptor antagonists linked with?
2Studies link beta-1 adrenergic receptor antagonists with 2 measures: lacunar stroke and vascular dementia.
Lacunar stroke
downin silico1OR 0.91
1 study
Lacunar stroke
downin silico1OR 0.91
Beta-1 adrenergic receptor antagonists lower the risk of lacunar stroke in silico (Mendelian randomization) (OR 0.91, 95% CI 0.80-1.03).
“lacunar stroke: OR = 0.91, 95% CI = 0.80-1.03”
In silicoMendelian randomization
Nature aging
Vascular dementia
downin silico1OR 0.9
1 study
Vascular dementia
downin silico1OR 0.9
Beta-1 adrenergic receptor antagonists lower the risk of vascular dementia in silico (Mendelian randomization) (OR 0.90, 95% CI 0.80-1.01).
“Beta-1 adrenergic receptor indicated potential benefit (clinical diagnosis: odds ratio (OR) = 0.90, 95% confidence interval (CI) = 0.80-1.01”
In silicoMendelian randomization
Nature aging